MAGLIO, ANGELANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 603
AS - Asia 447
EU - Europa 192
SA - Sud America 148
Continente sconosciuto - Info sul continente non disponibili 35
AF - Africa 10
OC - Oceania 1
Totale 1.436
Nazione #
US - Stati Uniti d'America 577
SG - Singapore 180
BR - Brasile 108
IT - Italia 95
VN - Vietnam 93
CN - Cina 72
IN - India 33
BD - Bangladesh 19
FI - Finlandia 19
DE - Germania 18
AR - Argentina 16
HK - Hong Kong 15
CA - Canada 13
GB - Regno Unito 11
EC - Ecuador 9
MX - Messico 8
ID - Indonesia 7
NL - Olanda 7
IE - Irlanda 6
IQ - Iraq 6
RU - Federazione Russa 6
FR - Francia 5
SE - Svezia 5
KE - Kenya 4
UA - Ucraina 4
VE - Venezuela 4
AT - Austria 3
CO - Colombia 3
ES - Italia 3
PE - Perù 3
PK - Pakistan 3
TR - Turchia 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
JO - Giordania 2
KR - Corea 2
NP - Nepal 2
PL - Polonia 2
PY - Paraguay 2
AL - Albania 1
AU - Australia 1
BE - Belgio 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
ET - Etiopia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
JP - Giappone 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
MA - Marocco 1
NI - Nicaragua 1
PA - Panama 1
PH - Filippine 1
SA - Arabia Saudita 1
SI - Slovenia 1
TN - Tunisia 1
Totale 1.401
Città #
San Jose 122
Singapore 91
Dallas 74
Ashburn 57
Ho Chi Minh City 46
Council Bluffs 33
Santa Clara 33
Bengaluru 25
Hefei 24
Beijing 17
Phoenix 15
Hanoi 14
Munich 14
Hong Kong 13
Turku 12
Milan 11
Chandler 10
Chicago 10
São Paulo 9
Los Angeles 8
Naples 8
New York 8
Helsinki 7
Boardman 6
Dublin 6
Haiphong 6
Lawrence 6
Ninh Bình 6
Princeton 6
San Francisco 6
London 5
Messina 5
Rome 5
Wilmington 5
Biên Hòa 4
Città Sant'Angelo 4
Houston 4
Nairobi 4
Palermo 4
Ankara 3
Baghdad 3
Belo Horizonte 3
Boston 3
Brooklyn 3
Guayaquil 3
Miami 3
Quito 3
Rimini 3
Rio de Janeiro 3
San Nicola Manfredi 3
São Luís 3
Thái Bình 3
Toronto 3
Amman 2
Amsterdam 2
Belford Roxo 2
Buffalo 2
Colniza 2
Dhaka 2
Fisciano 2
Florence 2
Fortaleza 2
Hanover 2
Johannesburg 2
Lamezia Terme 2
Lima 2
Manaus 2
Manchester 2
Maracaibo 2
Medellín 2
Mexico City 2
Mirassol 2
Mumbai 2
Olomouc 2
Porto Alegre 2
Santa Maria 2
Seoul 2
São Bernardo do Campo 2
The Bronx 2
Thái Nguyên 2
Uberlândia 2
Warsaw 2
Addis Ababa 1
Aguascalientes 1
Ahmedabad 1
Al Kazimiyah 1
Ambato 1
Ananindeua 1
Anicuns 1
Aparecida de Goiânia 1
Arinos 1
As Sālimīyah 1
Astana 1
Asunción 1
Athens 1
Atlanta 1
Aylmer 1
Baltimore 1
Bari 1
Barquisimeto 1
Totale 861
Nome #
Arg16Gly 132-Adrenoreceptor Polymorphism in Severe Eosinophilic Asthma: Implications for Mepolizumab Long-Term Effectiveness and Clinical Remission 109
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience 79
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study 76
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis 68
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study 68
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab 66
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets 62
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study 60
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma 60
Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease 57
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting 56
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13 55
Phenotyping severe asthma: a rationale for biologic therapy 52
Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma 52
Tezepelumab: A potential new biological therapy for severe refractory asthma 51
Difficult-To-Treat and Severe Asthma: Can Real-World Studies On Effectiveness of Biological Treatments Change the Lives of Patients? 50
Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy 48
Novel Biological Therapies for Severe Asthma Endotypes 46
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis 46
Chronic obstructive pulmonary disease and heart failure: Common diseases of the elderly, frequent non-recognition and the value of specialist referral 44
Novel Biological Therapies for Severe Asthma Endotypes 38
Pharmacotherapeutic strategies for critical asthma syndrome: a look at the state of the art 37
Effects of inhaled beclomethasone dipropionate/formoterol fumarate/glycopyrronium on diaphragmatic workload and lung function in uncontrolled asthma: a case report 36
Real-World Efficacy of Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium on Diaphragmatic Workload Assessed by Ultrasound and Lung Function in Patients with Uncontrolled Asthma 34
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps 32
Effect of the Arg16Gly β2‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study 19
Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach 19
Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma 16
Totale 1.436
Categoria #
all - tutte 10.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.153


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202221 0 0 0 4 2 1 1 5 3 3 2 0
2022/202344 14 3 8 0 2 1 1 2 3 1 8 1
2023/202447 13 4 6 2 2 6 1 2 1 4 4 2
2024/2025245 22 4 0 4 32 43 13 7 13 4 41 62
2025/2026881 46 87 130 181 91 52 77 49 87 48 16 17
2026/2027193 11 59 97 26 0 0 0 0 0 0 0 0
Totale 1.436